Publications and conference presentations
Papers in peered-reviewed journals
Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. Journal of Medical Economics Vol. 14, No. 6, 2011, 824–834
Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):601-15.
Lereun C, Wells P, Diamantopoulos A, Rasul F, Lees M, Sengupta N. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. J Med Econ. 2011; 14(2): 238-44. Epub 2011 Mar 9
Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-Effectiveness of Rivaroxaban versus Enoxaparin for the Prevention of Postsurgical Venous Thromboembolism in Canada. Thrombosis & Haemostasis. In print. October 2010
Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. Curr Med Res Opin. 2008; 24(9): 2639-50
Brown B, Diamantopoulos A, Bernier J, Schöflski P, Hieke K, Mantovani L, Launois R, Griebsch I, Robinson P. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. Value in health. 2008; 11(5): 791-799
Tang CH, Liu JT, Chang CW, Chang WY. Willingness to pay for drug abuse treatment: result from a contingent valuation study in Taiwan. Health Policy. 2007; 82(2): 251-262
Neophytou I, Harvey R, Lawrence J, Marsh P, Panaretou B, Barlow D. (2007). Eukaryotic integral membrane protein expression utilizing the Escherichia coli glycerol-conducting channel protein (GlpF). Appl Microbiol Biotechnol; 77(2):375-81.
Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, Diamantopoulos A. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics. 2007; 25(1): 39-54
Podium presentations
Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparisons of rivaroxaban vs alternative prophylaxes for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) or total knee replacement (TKR). Fifth Annual Meeting of Health Technology Assessment International. Montreal, Canada. July 2008
Chang SCW. Comparing economic and non-economic outcome measurements in the evaluation of drug misuse interventions. Alcuin Research Resource Centre (ARRC) Conference, University of York. York, UK. July 2009
Pompen M, Diamantopoulos A, Kievit W, Moers R, Kielhorn A. Economic consequences of providing rituximab as a treatment alternative for rheumatoid arthritis in the Netherlands. ISPOR 10th Annual European Congress. Dublin, Ireland. October 2007
Poster presentations
Chang S, Sungher D, Diamantopoulos A, Learning effect in economic evaluations of health care interventions. Research poster for the ISPOR 14th Annual European Congress.
Diamantopoulos A, Kievit W, De Vries R, Pompen M. Cost-effectiveness of rituximab in the treatment of RA patients in the Netherlands. Research poster for the ISPOR 14th Annual European Congress.
LeReun C, Neophytou I, de Vries R, Diamantopoulos A, Pompen M. A network meta-analysis of biologic treatments in TNF-IR rheumatoid arthritis patients. Research poster for the ISPOR 14th Annual European Congress.
Diamantopoulos A, Andrade S, Bernardo A, et al. Cost-effectiveness of tocilizumab compared to standard therapeutic sequences for the treatment of moderate/severe rheumatoid arthritis (RA) patients in Portugal. Research poster for the ISPOR 14th Annual European Congress.
Wieser S, Brühlmann P, Kyburz D, Plessow R, Pletscher M, Diamantopoulos A, Brügger U. Cost-effectiveness of Tocilizumab in Switzerland: A Microsimulation Approach. Research poster for the ISPOR 13th Annual European Congress.
Neophytou I, LeReun C, Diamantopoulos A. Analysis of inappropriate shocks in implantable cardioverter defibrillator (ICD) devices. Research poster for the ISPOR 13th Annual European Congress.
Wieser S, Brühlmann P, Kyburz D, Plessow R, Pletscher M, Diamantopoulos A, Brügger U. Cost-effectiveness of Tocilizumab in Switzerland: A Microsimulation Approach. Poster (Nr. P 25) für den Jahreskongress SGR 2010 in Fribourg angenommen wurde
Diamantopoulos A, Forster F, Duran A, Brosa M, Lees M, Gilmour L, Ashley D,. Piñol C. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. Barcelona, Spain. March 2009.
Diamantopoulos A, Forster F, Brosa M, Lees M, Piñol C, Febrer L. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Spain. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC6.
Diamantopoulos A, Forster F, Lees M, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Canada. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC7
Diamantopoulos A, Forster F, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC9.
Diamantopoulos A, Forster F, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC8.
Negrini C, Diamantopoulos A, Forster F, Lopatriello S, Lees M, Bianchi C, Pedone MP. Prophylaxis with rivaroxaban against venous thromboembolism (VTE): a cost-consequence analysis from the Italian Healthcare Service perspective. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC10.
Kwong L, Diamantopoulos A, Forster F, Sengupta N, Lees M. Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients? Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1290.
Wells P, Diamantopoulos A, Forster F, Lees M, McDonald H Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1291.
Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M, Wells P Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1292.
Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparison of rivaroxaban regimens vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement. 20th International Congress on Thrombosis (ICT). Athens, Greece; 25–28 June 2008.
Diamantopoulos A, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparison of rivaroxaban vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement. ISPOR 13th Annual International meeting. Toronto, Canada. 2008
Lewis G, Kielhorn A, Diamantopoulos A. Cost-effectiveness of rituximab (mabthera) compared with abatacept (orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the UK. ISPOR 10th Annual European Congress. Dublin, Ireland. October 2007. [Research Contribution award]
Diamantopoulos A, Cottrell S, Lorenzo M. A cost-utility analysis of atomoxetine against current stimulant therapies for the treatment of children with attention deficit/hyperactivity disorder (ADHD) in Germany. ISPOR 10th Annual European Congres, Dublin, Ireland, October 2007
Porter D, Lewis G, Brown B, Diamantopoulos A, Kielhorn A, Cost-effectiveness analysis of rituximab as a new therapeutic option for rheumatoid arthritis in the UK. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006
De Vita S, Giuliani G, Diamantopoulos A, Brown B, Kielhorn A. Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006
Kielhorn A, Alvarez C, Aristides M, Diamantopoulos A. Using mabthera in patients with rheumatic arthritis in Spain: results of cost-effectiveness data based on micro-simulation. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006
Brosa M, Robinson P, Brown B, Diamantopoulos A. Cost-effectiveness of cetuximab in combination with radiotherapy versus radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain. ISPOR 11th Annual international meeting Philadelphia, PA, USA, May 2006
Schach S, Rubbert A, Diamantopoulos A, Aristides M, Kielhorn A Cost implications of introducing rituximab as a new treatment modality for rheumatoid arthritis in Germany. Ann Rheum Dis 2006;65(Suppl II):600
Lewis G, Porter D, Brown B, Diamantopoulos A, Kielhorn A. Economic consequences of providing rituximab as a new therapeutic option for rheumatoid arthritis in the UK. Ann Rheum Dis 2006;65(Suppl II):283
Mistry B, McCormick J, Diamantopoulos A, Kielhorn A. Cost-utility analysis of rituximab as a new therapeutic option for rheumatoid arthritis patients in Canada. ISPOR 9th Annual European Congress. Copenhagen, Denmark October 2006
Chang CW. Comparing cost-effectiveness of interventions to reduce mother-to-child transmission of HIV in South and South-East Asia. ISPOR 2nd Asia-Pacific Conference. Shanghai, China. March 2006
Tilden D, Mariz S, Diamantopoulos A, O'Bryan-Tear G. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. ISPOR 8th Annual European Congress. Florence, Italy 2005
Updated November 2011